Sunitinib
Back to searchMolecule Structure
Scientific Name
Sunitinib
Description of the Drug
Sunitinib is a receptor tyrosine kinase inhibitor and chemotherapeutic agent used for the treatment of renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST).
Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB01268
http://www.drugbank.ca/drugs/DB01268
Brand Name(s)
Sutent
Company Owner(s)
Cp Pharmaceuticals International Cv, Sun Pharmaceutical Industries Ltd, Dr Reddys Laboratories Ltd, Mylan Pharmaceuticals Inc, Teva Pharmaceuticals Usa
Mechanism(s) Of Action
| Target Name | Target Type | Action Type | Target ChEMBL ID |
|---|---|---|---|
| Stem cell growth factor receptor | SINGLE PROTEIN | INHIBITOR | CHEMBL1936 |
| Platelet-derived growth factor receptor | PROTEIN COMPLEX | INHIBITOR | CHEMBL2095189 |
| Tyrosine-protein kinase receptor FLT3 | SINGLE PROTEIN | INHIBITOR | CHEMBL1974 |
| Tyrosine-protein kinase receptor RET | SINGLE PROTEIN | INHIBITOR | CHEMBL2041 |
| Vascular endothelial growth factor receptor | PROTEIN FAMILY | INHIBITOR | CHEMBL2095227 |
| Macrophage colony stimulating factor receptor | SINGLE PROTEIN | INHIBITOR | CHEMBL1844 |
Clinical Trial(s)
Unichem Links
| SureChEMBL | SCHEMBL8081 | |||
| PharmGKB | PA162372840 | |||
| Human Metabolome Database | HMDB0015397 | |||
| DrugBank | DB01268 | |||
| PubChem: Thomson Pharma | 14830382 | |||
| PubChem | 5329102 | |||
| NMRShiftDB | 60077060 | |||
| LINCS | LSM-42800 | |||
| Nikkaji | J1.942.549E | J2.036.576E | ||
| PDBe | B49 | |||
| BindingDB | 4814 | |||
| DrugCentral | 2544 | |||
| Brenda | 127384 | 7646 | 25420 | 40342 |
| ChemicalBook | CB6507435 | CB9728174 | ||
| Guide to Pharmacology | 5713 | |||
| rxnorm | SUTENT | SUNITINIB | SUNITINIB MALATE | |
| ChEBI | 38940 | |||
| ZINC | ZINC000003964325 |
